Astonea Labs Limited · BSE:ASTONEALAB

Astonea Labs — H1 FY2027 Earnings Presentation

24 slides from Astonea Labs's earnings presentation, Nov 18, 2026

  1. Slide 1: Submission of Investor Presentation to BSE

    Date: 18th November, 2026 To, BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 544409 ISIN: INE0TG901011 SUBJECT: SUBMISSION OF INVESTOR PRESENTATION FOR THE HALF-YEAR ENDED 30TH SEPTEMBER, 2026 UNDER REGULATION 30 OF THE SEBI (LISTIN

  2. Slide 2: Beyond Lifespan: Advancing Healthspan Through Innovation

    astonea HY1FY27 | 18TH NOV, 20 ASTONEA LABS LIMITED EARNINGS PRESENTATION Beyond Lifespan: Advancing Healthspan Through Innovation Half-Yearly Financial Results, Operational Milestones & Strategic Growth Outlook Standalone Unaudited Financial Resu BSE Scrip Code: 544409

  3. Slide 3: Safe Harbour Statement

    ASTONEA LABS LIMITED HALF-YEARLY EARNINGS PRESENTATION SAFE HARBOUR STATEMENT astonea This presentation has been prepared by Astonea Labs Limited ("the Company") for informational purposes only and should be read together with its published financial results and stock exchange filings. Statements re

  4. Slide 4: Management Commentary: Business & Financial Performance

    H1FY 2026-27 | BUSINESS & FINANCIAL PERFORMANCE MANAGEMENT COMMENTARY astonea REVENUE GROWTH EBITDA GROWTH +44.61% +140.88 % %95.86 Crore 213.20 Crore 4.76 Crore Transition to Ind AS: Voluntary adoption of Indian Accounting Standards (Ind AS), strengthening financial reporting, transparency and comp

  5. Slide 5: Financial Highlights & Growth Outlook

    STANDALONE PERFORMANCE | IND AS FINANCIAL HIGHLIGHTS & astonea GROWTH OUTLOOK Revenue from Operations 295.86 Cr 766.29 Cr +44.61% Total Income Z96.21Cr 766.39 Cr +44.92% EBITDA 213.20 Cr 75.48 Cr +140.88% Profit After Tax (PAT) 24.76 Cr Z1.90 Cr +150.53% EBITDA includes other income of 0.35 Cr (H1 F

  6. Slide 6: Profit & Loss Statement

    H1FY 2026-27 | STANDALONE, IND AS (% CRORE) PROFIT & LOSS STATEMENT astonea GROSS MARGIN EBITDA MARGIN* PAT MARGIN 37.6% 13.8% +1,086 bps YoY | H1 FY26: 26.7% +550 bps YoY | H1FY26: 8.3% Revenue from operations 95.86 66.29 +44.6% 81.29 +17.9% 147.58 Other income 0.35 0.10 0.44 0.54 Total income 96.2

  7. Slide 7: Balance Sheet & Key Ratios

    AS AT 30 SEPTEMBER 2026 | STANDALONE, IND AS (% CRORE) BALANCE SHEET & KEY RATIOS astonea Balance sheet 30 Sep 2026 | 31Mar2026 | 30 Sep 2025 Net worth 72.12 67.30 65.38 Gross borrowings 57.15 43.00 39.05 Lease liabilities 3.13 3.40 0.33 Cash and bank balances 0.47 0.18 0.65 Net debt (excl. leases)

  8. Slide 8: Balance Sheet & Key Ratios: Working Capital Days

    AS AT 30 SEPTEMBER 2026 | STANDALONE, IND AS (% CRORE) BALANCE SHEET & KEY RATIOS astonea Working capital days (on revenue) @ Receivable @ Inventory Payable @ Net working capital 200 150 146.0 121.0 100 100.0 101.0 83.0 83.0 72.0 77.0 ; a - al | i?) 30 Sep 2025 31 Mar 2026 30 Sep 2026 e Net debt / T

  9. Slide 9: Key Business Highlights: Financial & Market Growth

    H1FY 2026-27 | FINANCIAL & MARKET GROWTH KEY BUSINESS HIGHLIGHTS astonea Total Income: $96.21 Cr Revenue Growth EBITDA Expansion PAT Acceleration 95.86 Cr 13.20 Cr 74.76 Cr 02. NEW PRODUCT LAUNCH Young Fuel Anti-Ageing Cream Strong market debut in anti-ageing wellness. 03. INTERNATIONAL EXPANSION Gu

  10. Slide 10: Key Business Highlights: Operations & Compliance

    H1FY 2026-27 | OPERATIONS & COMPLIANCE KEY BUSINESS HIGHLIGHTS astonea 04. US OTC BUSINESS DEVELOPMENT Key Regulatory Audits Cleared Advancing commercialisation for planned US OTC expansion. 05. MANUFACTURING CAPACITY ENHANCEMENT +35% Tablet Output Capacity Scaled production capabilities to meet ris

  11. Slide 11: Corporate Vision

    ASTONEA LABS LIMITED « CORPORATE VISION INNOVATING HEALTH. ENHANCING daSlON€a LIVES. EMPOWERING LONGEVITY. At Astonea Labs Limited, we are committed to advancing healthcare through innovative pharmaceutical, nutraceutical and wellness solutions that address evolving healthcare needs. Driven by resea

  12. Slide 12: Strategic Pillars Driving Domestic & Global Expansion

    STRATEGIC PILLARS DRIVING DOMESTIC & GLOBAL EXPANSION KEY BUSINESS VERTICALS astonea ——y 01. OVER-THE-COUNTER OTC Business Product Portfolio & Global Market Expansion Portfolio Expansion: Growing domestic and international OTC healthcare range. US OTC Entry: Advancing toward commercialisation with m

  13. Slide 13: Market Leadership Roadmap

    MARKET LEADERSHIP ROADMAP LONGEVITY - OURGROWTH AMBITION daSlONCa Astonea Labs Limited aims to establish a strong leadership position in the rapidly evolving anti-ageing and longevity supplement market. FOUNDATION PHASE R Product innovation and regulatory approvals. Expansion oooeee ane FY 2027-28 T

  14. Slide 14: Manufacturing & Supply Chain: Key Highlights

    ASTONEA LABS LIMITED OPERATIONAL EXCELLENCE MANUFACTURING & SUPPLY astonea CHAIN — KEY HIGHLIGHTS Digital Transformation SAP integration with Al-based QMS verification systems underway. Automation & Compliance E-BMR/E-BAR and Al-driven compliance model targeted for deployment by Q2 FY28. Operations

  15. Slide 15: Regulatory Approvals & Quality Assurance

    ASTONEA LABS LIMITED GLOBAL AUDIT & QUALITY BENCHMARKS REGULATORY APPROVALS & astonea QUALITY ASSURANCE Quality & Regulatory Compliance Revised Schedule M & WHO-GMP: Full compliance across manufacturing operations. US Regulatory Readiness: Strengthening alignment with US FDA cGMP standards. ISAFI cG

  16. Slide 16: R&D: Formulation Advancements & Regulatory Filings

    H1 FY 2026-27 FORMULATION ADVANCEMENTS & REGULATORY FILINGS R&D — KEY HIGHLIGHTS & astonea MAJOR DEVELOPMENTS Target Completion: H2 FY 2026-27 3 Strengths 400 | 600 | 800 mg Analytical validation 1. Product Development Ibuprofen 400 mg, 600 mg & 800 mg softgel formulations under multi-step quality a

  17. Slide 17: Product Development & Launch Timeline

    ASTONEA LABS LIMITED PRODUCT DEVELOPMENT & LAUNCH TIMELINE R&D — ROADMAP & astonea COMMERCIALISATION OUTLOOK PHASE 1 | H2 FY 2026-27 Validation & Finalisation & Targeted completion of formulation finalisation and analytical validation. 6 Completion of dossier-related activities for the proposed prod

  18. Slide 18: Regulatory Submissions & Product Registrations

    4 LATIN AMERICAN MARKETS | 95 TOTAL DOSSIERS REGULATORY SUBMISSIONS & astonea PRODUCT REGISTRATIONS Country Dossiers Submitted Share Distribution Nicaragua SE Bolivia 2 Guatemala DO Panama 12 ae: Total 95 Across 4 LATAM Markets 95 Dossiers: Submitted across four international markets. LATAM Approval

  19. Slide 19: Strengthening Our Global Footprint

    STRENGTHENING OUR GLOBAL FOOTPRINT INTERNATIONAL MARKET EXPANSION astonea Labs expanding Astonea Limited is strategically its international presence across Central America, South America, and the Caribbean, creating new avenues _ for and global business growth strengthening its distribution network.

  20. Slide 20: Expanding International Business & Distribution Network

    EXPANDING INTERNATIONAL BUSINESS & DISTRIBUTION NETWORK KEY BUSINESS HIGHLIGHTS astonea Strengthening Our Global Distribution Footprint QQ Expanding international presence through branded pharmaceutical, nutraceutical and wellness product offerings. @ Established distribution network spanning 9 mark

  21. Slide 21: Building a Stronger Global Distribution Network

    BUILDING A STRONGER GLOBAL DISTRIBUTION NETWORK INTERNATIONAL GROWTH astonea STRATEGY & OUTLOOK ~ Strengthen international presence, diversify revenue streams, and unlock long-term global growth. Distribution Partnerships Developing strategic distribution alliances across emerging international mark

  22. Slide 22: Forward Strategy: Business Outlook & Strategic Priorities

    ASTONEA LABS LIMITED FORWARD STRATEGY BUSINESS OUTLOOK & astonea STRATEGIC PRIORITIES - fr | | | OTC Growth (~5% MoM) | Export Growth Pipeline | | | Consistent ~5% month-on-month Strong pipeline of international | | momentum across core OTC portfolio. product registrations driving | | expansion. | |

  23. Slide 23: Financial Guidance: Revenue Targets and FY27 Margins

    FY 2026-27 TO FY 2028-29 | REVENUE TARGETS AND FY27 MARGINS FINANCIAL GUIDANCE astonea FY 2027 FY 2028 FY 2029 Z215 Croret 2300 Croret +35% on FY28 target Revenue from operations (% Cr) 500 400 300 200 100 FY24 FY25 FY26 FY27 Target FY28 Target FY29 Target %95.86 Cr delivered in HI FY27 (+44.6% YoY)

  24. Slide 24: Contact: Email, Website and Addresses

    EMAIL WEBSITE investorgrievance@astonea.org https:/ / astonea.org/ CORPORATE ADDRESS Q. REGISTERED ADDRESS 63, Industrial Area, Phase-2, SCO 321-322, Sector-35 B, Panchkula, Haryana, India, 134113 Chandigarh, India, 160022 BSE SCRIP CODE (oa CIN ~ 544409 L21001CH2017PLC041482

Astonea Labs — H1 FY2027 Earnings Presentation on 6ix